Hydergine Lc

(Ergoloid Mesylates)

Phase 2Small molecule

Novartis

Hydergine Lc is one of 47 small molecule programs targeting Fragile X Syndrome. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Fragile X SyndromeActive, not recruiting

Vascular DementiaActive, not recruiting

Fragile X SyndromePhase 2

Active, not recruiting

Vascular DementiaPhase 2

Active, not recruiting

Competition

Competitive Landscape

46 competitors in Fragile X Syndrome

#DrugCompanyPhaseTrials

Namenda

Lioresal

Epidiolex

Daliresp

Glucophage

4 6

Rilutek

AAzurity Pharmaceuticals

Approved

1 7

Minocin

TTriax

Approved

1 8

Altoprev

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 9

Lithobid

SSolvay Pharmaceuticals

Approved

—10

Clinoril

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vascular Dementia1 trial

Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)

Completed·SSinphar Pharmaceutical Co., Ltd·Phase 2·NCT01475578·240 enrolled

Fragile X Syndrome1 trial

ERG/5-HTP in Fragile X Syndrome (FXS)

Completed·EElizabeth Berry-Kravis·Phase 2·NCT05030129·15 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

HYDERGINE

NDA NDA018418

Jan 1, 1982

HYDERGINE

NDA NDA017993

Jan 1, 1982

HYDERGINE

NDA NDA009087

Jan 18, 1983

HYDERGINE LC

NDA NDA018706

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ergoloid Mesylates. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ergoloid Mesylates compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ergoloid Mesylates. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018706). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

Hydergine Lc

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vascular Dementia1 trial

Fragile X Syndrome1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News